SCHEMBL1067446

SCHEMBL1067446

COC(=O)[C@H](CC(C)C)N1CC(Oc2ccc(F)cc2F)=CC1=O

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.36
CARM1 Q86X55 3/20 0.35
PRMT6 Q96LA8 3/20 0.35
MAPK14 Q16539 5/20 0.35
MAPK8 P45983 2/20 0.35
CREBBP Q92793 1/20 0.35
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BRD4 O60885 4/20 0.34
RPS6KA4 O75676 1/20 0.34
MAPK9 P45984 1/20 0.34
CSNK1E P49674 1/20 0.34
RPS6KA3 P51812 1/20 0.34
MAPK10 P53779 1/20 0.34
MAPK11 Q15759 1/20 0.34
NLK Q9UBE8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067449 1.00 S1PR2 (0.36) S1PR2CARM1PRMT6MAPK14MAPK8
SCHEMBL1067087 0.92 NOS3 (0.33) MAPK14
SCHEMBL1067085 0.92 NOS3 (0.33) MAPK14
SCHEMBL1067375 0.91 S1PR2 (0.38) S1PR2CARM1PRMT6MAPK14MAPK8
SCHEMBL1067371 0.91 S1PR2 (0.38) S1PR2CARM1PRMT6MAPK14MAPK8
SCHEMBL1065767 0.90 MAPT (0.38) CARM1PRMT6MEN1MAPTKMT2A
SCHEMBL2700898 0.90 MAPT (0.38) CARM1PRMT6MEN1MAPTKMT2A
SCHEMBL1067028 0.85 LMNA (0.33) MEN1MAPTKMT2AL3MBTL1
SCHEMBL1067031 0.85 LMNA (0.33) MEN1MAPTKMT2AL3MBTL1
SCHEMBL1066291 0.84 GNRHR (0.35) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 S1PR2 3011/4885CARM1 1716/4885PRMT6 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.